PainReform Shares Down 24.9% Premarket After Pain Relief Treatment Fails to Meet Main Goal in Late Stage Trial
PainReform的股票在盤前交易中下跌24.9%,因止痛治療未能在晚期試驗中達到主要目標。
PainReform Shares Down 24.9% Premarket After Pain Relief Treatment Fails to Meet Main Goal in Late Stage Trial
PainReform的股票在盤前交易中下跌24.9%,因止痛治療未能在晚期試驗中達到主要目標。
譯文內容由第三人軟體翻譯。